Introduction
Rituximab is a chimeric therapeutic antibody used for treating individuals with CD20 + hematologic cancers (1) , whereas trastuzumab is a humanized therapeutic antibody used for treating individuals with HER2 + cancers (2, 3) . Numerous reports have demonstrated that rituximab and trastuzumab can mediate their effects through multiple mechanisms (3, 4) . Along with the ability to disrupt survival and growth signaling in cancerous cells, these antibodies can facilitate antibody-dependent cellular cytotoxicity (ADCC) to destroy tumor cells (3, 4) . In this context, rituximab and trastuzumab mobilize the innate immune system to attack tumors by promoting the interaction of immune cells and cancer cells expressing CD20 or overexpressing HER2, respectively. This method of cytotoxicity is mediated at the cellular level through the interaction of FcγRIIIa expressed on natural killer (NK) cells or macrophages and the Fc portion of the tumor-bound antibody (3, 4, 5) . This directs secretion of lytic molecules toward the antibody-decorated tumor cell, resulting in lysis of the tumor cell (6) .
The importance of mobilizing the immune system for ADCC in tumor eradication is documented in numerous preclinical and clinical studies using different therapeutic antibodies. In preclinical in vivo studies, lower antitumor activity with therapeutic antibodies was observed in FcγR chain-deficient mice compared to wild-type mice (7) . Similarly, treatment of mice with an "effectorless" form of the therapeutic antibody that does not interact with the Fc receptor also resulted in lower antitumor activity compared to mice treated with unmodified antibody (7) . In two clinical studies, follicular or B-cell lymphoma patients with the high affinity allele of FcγRIIIa have a better response rate with rituximab relative to patients with low affinity allele (8, 9 ), yet a third such study observed no significant variation as a function of the FcγRIIIa allele (10) . The relationship between FcγRIIIa affinity and efficacy of trastuzumab in humans is 4 similarly unclear. One study showed that for metastatic breast cancer patients treated with trastuzumab and a taxane, patients with the high affinity allele had better response rates and progression free survival (PFS), compared to patients with the low affinity allele (11) . By contrast, two other studies showed no significant advantages in response rate, PFS, or diseasefree survival for trastuzumab-treated metastatic breast cancer patients with the high affinity allele (10, 12, 13) . Although explanations for these apparent discrepancies remain to be identified, preclinical data and other evidence that ADCC plays a prominent role in the mechanism of action of some therapeutic antibodies have led to efforts to increase binding of antibodies to FcγRIIIa to augment ADCC (14, 15, 16) . To this end, removing fucose from asparagine 297 of the heavy chain results in an increase in binding affinity between the Fc portion of the antibody and FcγRIIIa, which consequently leads to more efficient ADCC (14, 15, 16, 17) . Because of these and other related studies, obinutuzumab, an afucosylated anti-CD20 antibody, was developed and shown to have superior efficacy in clinical trials compared to rituximab (14, 18) , and is currently approved to treat patients with chronic lymphocytic leukemia. These observations imply that potentiating ADCC via the innate immune system represents a promising approach in the development of therapeutics for oncology indications.
Multiple signaling pathways and components are known to govern cellular processes required for ADCC (5) . Stimulation of NK cells through FcγRIIIa begins with phosphorylation of proximal signaling components, including the src family kinase Lck (19) , the CD3ζ chain (20, 21) , and Zap70 (22) . This leads to the activation of multiple protein tyrosine signaling cascades required for NK-cell cytotoxicity (23) , including the MAPK and PI3K pathways, which govern degranulation (24, 25, 26) , and Vav-1, which regulates actin rearrangement (27, 28, 29) . As expected, both actin rearrangement and degranulation are cellular processes required for NK-cell cytotoxicity (6, 30) . Thus, activation of multiple signaling components and pathways that govern actin rearrangement and degranulation through FcγRIIIa is essential for NK cellmediated ADCC.
Although the relationship between the increased affinity of afucosylated antibodies for FcγRIIIa and enhanced ADCC (15, 17) is well-established, the cellular and molecular basis for this observed enhancement is unknown. We demonstrate here that human NK cells stimulated with afucosylated trastuzumab or obinutuzmab exhibit an increase in activation of proximal FcγRIIIa signaling components and downstream signaling pathways, including specifically the Vav-1, MAPK, and PI3K pathways. Consistent with these findings, NK cells stimulated by afucosylated antibodies displayed an increase in actin rearrangement and degranulation. Finally, using a high throughput microscope-based cytotoxicity assay developed to characterize certain cellular parameters of ADCC, we observe that afucosylated antibodies enhance the cytotoxic potential of an entire NK-cell population by increasing the frequency of NK cells that can kill multiple targets. Moreover, afucosylated antibodies increase the cytotoxic potential of individual NK cells by decreasing the duration required to kill individual targets. Together, our findings indicate that increased affinity between afucosylated antibodies and FcγRIIIa enhances activation of signaling molecules to promote actin rearrangement and degranulation, and enhances serial killing and more rapid killing, leading to an overall enhancement of ADCC.
Methods
Immunoblotting. NK cells were enriched from human blood (all donors used were of FcγRIIIa F/F158 phenotype, except in Supplemental Figure 1 , in which samples from V/V158 donors were used) using LSM (MP Biomedicals) followed by labeling with NK isolation kit and sorting with AutoMACs (Miltenyi Biotec). Purity of NK cells is >90%. NK cells were incubated with 1 μg/mL antibody for 30 minutes on ice and washed with media. Anti-human κ light chain antibody (50 μg/mL; Millipore) was added and cells were incubated for indicated timepoints at 37°C. Anti-human κ light chain antibody binds similarly between afucosylated antibody and their respective counterpart (data not shown). Ice-cold media was added to stop the stimulation.
Cells were pelleted and lysate was made using RIPA buffer (Sigma) containing phosphatase Intracellular phospho-ERK1/2 staining. Cells were stimulated as described. After the final wash, cells were pelleted and fixed with 2% paraformaldehyde for 10 minutes, chilled for 1 minute and spun. Ice-cold 90% methanol was added and incubated on ice for 30 min. Cells were washed and stained with phospho-ERK1/2 antibody for 60 minutes. Data were acquired on an LSR flow cytometer (BD Biosciences) and analyzed using FlowJo.
Actin rearrangement assay. Cells were stimulated as described. After the final wash, cells were pelleted, fixed with 3.7% paraformaldehyde for 10 minutes at RT, and washed with PBS. Cells were permeabilized with 0.1% Triton X-100/PBS for 5 minutes, pelleted, and stained with 5 units/mL phalloidin (1% BSA/PBS) (Invitrogen) for 20 minutes. Cells were washed with PBS before acquisition.
CD107a expression assay. NK cells (1x10 6 ) were incubated with 1 μg/mL antibody for 30 minutes on ice and washed. Media containing anti-human K light chain antibody (Millipore) and CD107a APC (BD Biosciences) was added and cells were incubated at 37°C. At the indicated timepoints, 4% paraformaldehyde was added and incubated for 10 minutes at RT. Cells were washed with PBS before acquisition.
Microscope-based ADCC assay. This assay was modified from that used by Bhat and colleagues (31) . NK cells were labeled with PKH26 Red Fluorescent Cell Linker Kit (Sigma) and mixed at 0.4:1 E:T ratio with targets (BT474 for trastuzumab, WIL2-S for anti-CD20 studies), 
Results

Afucosylated antibody-stimulated NK cells exhibit increased activation of tyrosine kinases and proximal FcγRIIIa signaling
Early studies of FcγRIIIa signaling demonstrated that herbimycin A, a broad spectrum tyrosine kinase inhibitor, abrogates ADCC antibody-stimulated NK cells, suggesting that tyrosine kinase activation and tyrosine phosphorylation are required for cytotoxicity (23) . To determine whether afucosylated antibodies alter tyrosine kinase-dependent signaling, the phospho-protein repertoire of antibody-stimulated NK cells was assessed by preparing cell extracts and subjecting them to immunoblotting with an anti-phosphotyrosine antibody. As shown in Fig. 1A , we observed an increase in total protein tyrosine phosphorylation in NK cells treated with afucosylated trastuzumab (Fig. 1A) or obinutuzumab ( Afucosylated antibodies do not appear to alter the kinetics of representative tyrosine phosphorylated proteins when compared to their respective fucosylated partners. Specifically, the phosphorylation kinetics of the 85 kDa and 60 kDa phospho-proteins were comparable following treatment with both forms of trastuzumab (Fig. 1D) . Similar results were observed when comparing obinutuzumab and rituximab treated NK cells (Fig. 1E) . Together, these findings imply that the increase in binding affinity between FcγRIIIa and antibody enhances FcγRIIIa-dependent signal strength, as reflected by the total phospho-tyrosine content, but not phosphorylation kinetics. 
Afucosylated antibody stimulated-NK cells exhibit increased activation of signaling components and pathways required for FcγRIIIa-mediated cytotoxicity
After activation by Lck, Zap70 phosphorylates linker of activated T cells (LAT) to initiate numerous downstream signaling pathways (32) , including the Vav-1 pathway that is required for actin rearrangement (27, 28, 29) , and the MAPK and PI3K pathways that are essential for degranulation (24, 26) . To further characterize the enhanced signaling mediated by (Fig. 3A) . Similarly, we observed an increase in phospho-Akt in NK cells stimulated with afucosylated trastuzumab and obinutuzumab compared to their fucosylated controls (Fig. 3B, 3F ). Furthermore, MAPK pathway activation was also enhanced in afucosylated trastuzumab-and obinutuzumab-stimulated cells (Fig. 3C,   3G ).
To quantify the activation status on a per cell basis, we used flow cytometry to assess the expression of intracellular phospho-ERK1/2. In these experiments, we observed that phospho-ERK1/2 expression was evident in a larger fraction of afucosylated trastuzumab-stimulated NK cells (Fig. 3D) , and the phospho-ERK1/2 MFI was higher in these cells (Fig. 3E ). These findings indicate that afucosylated trastuzumab activates more cells than fucosylated trastuzumab, and that the cells in the population are, on average, activated to a greater extent.
These observations are consistent with the conclusion that an increase in affinity between FcγRIIIa and antibody promotes stronger FcγRIIIa signaling.
Afucosylated antibody stimulated-NK cells exhibit increased actin rearrangement and degranulation
Two key cellular mechanisms required for NK cell cytotoxicity are actin rearrangement and degranulation (6) . To determine whether afucosylated antibodies are more effective than increase in phospho-Vav-1, we observed an increase in F-actin content in NK cells stimulated with afucosylated trastuzumab (Fig. 4A) . Furthermore, at all timepoints examined, the MFI ratio of F-actin content was higher (Fig. 4B ) in cells stimulated with afucosylated trastuzumab, indicating that the afucosylated antibody promoted more actin rearrangement in NK cells relative to the antibody of the fucosylated form.
To determine whether afucosylated antibodies enhance the efficiency of degranulation, we used flow cytometry to measure the relocalization of the lysomal marker, CD107a, to the cell surface. We observed a greater fraction of NK cells expressing surface CD107a when stimulated with afucosylated trastuzumab (Fig. 4C) . Similarly, a higher percentage of obinutuzumabactivated NK cells expressed CD107a compared to rituximab-stimulated cells (Fig. 4D) . We also observed that the MFI of the CD107a was greater on NK cells stimulated with afucosylated trastuzumab (Fig. 4E) and obinutuzumab ( 
Microscope-based cytotoxicity assay detects increased afucosylated antibody-mediated ADCC at low E:T ratio
Conventional assays that measure ADCC use high E:T ratios (i.e. 10:1 to 25:1), which can be considered non-physiologic given that NK cells are a rare cell type in solid tumors, relative to tumor cells (33, 34) . Conventional ADCC assays also do not allow for visualization of the interaction between NK cells and targets, thus prohibiting the identification and characterization of changes in the duration required for cytotoxicity or individual NK-cell cytotoxic potential. To address these deficiencies, we adapted a microscope-based cytotoxicity assay (31) to visualize the interaction between NK cells and targets, thus enabling us to quantify target killing, and to characterize other parameters of ADCC under more physiologic conditions.
As shown in Fig. 5A , continuous monitoring of interactions between live NK cells and their live targets allowed us to observe the progression of killing at time points spanning a 6-hour interval.
Quantitatively, cultures containing antibody yielded substantially more cell death compared to negative control cultures without antibody, demonstrating that the assay assesses ADCC (Fig.   5B ). Using this assay, we observe more cytotoxicity in the presence of afucosylated trastuzumab relative to cytotoxicity in the presence of fucosylated trastuzumab (Fig. 5C) . Similarly, obinutuzumab-treated NK cells killed more WIL2-S CD20-expressing target cells relative to target cells killed by NK cells stimulated with rituximab (Fig. 5D ). However, obinutuzumab is a type II antibody that induces more apoptosis in target cells without the need for NK cells, relative to rituximab (14) , a type I antibody. Nonetheless, the increase in the number of dead cells observed with obinutuzumab treatment is not simply a reflection of more potent antibodydependent, immune cell-independent cytotoxicity, since targets with antibody-only conditions (NK cell-independent killing) were included as controls and factored into the equation for percent cytotoxicity (see methods). Therefore, our analysis of percent cytotoxicity accounts for any apoptosis attributable to killing mediated solely by antibody. As the data show, ADCC is enhanced with obinutuzumab ( Fig. 5E) , indicating that the increase in cytotoxicity observed with obinutuzumab, relative to rituximab, is not due to the epitope-binding specific differences between these type I and type II antibodies. 
Afucosylated antibodies increase frequency of multiple killing events and decrease time required for target cell lysis
To address the possibility that afucosylated antibodies increase ADCC by increasing the cytotoxic potential of the NK-cell population, experiments were performed to address multiple killing events. We found that serial killing events are mediated by single NK cells in assays containing either afucosylated (Fig. 6A, top) or fucosylated trastuzumab (Fig. 6A, bottom) .
However, we observed that the frequency of NK cells killing multiple targets is higher in assays containing afucosylated trastuzumab relative to assays containing the fucosylated antibody (Fig.   6C ).
We also sought to determine whether the time required to lyse a target cell is modulated by the fucosylation state of the antibody, thereby leading to potentiation of ADCC. To assess the duration required for cytotoxicity, live-cell microscopy videos were interrogated for cytotoxic events in which target engagement, lysis, and release were visualized and measured (Fig. 6B ).
As shown in Figure 6B and D, NK cells in cultures containing fucosylated trastuzumab took twice as long to kill target cells relative to cultures containing the afucosylated form (50 vs. 100 min, Fig. 6D ). These findings are consistent with the earlier observation that there are more dead cells at early time points in assays containing afucosylated trastuzumab relative to the same time point in assays containing fucosylated trastuzumab (Fig. 5A) . Considered together, these observations indicate that NK cells in assays containing afucosylated trastuzumab kill faster and more often.
Similar results were obtained using this assay to compare obinutuzumab and rituximab, when using the target cell line WIL2-S. In assays containing obinutuzumab, NK cells achieved more multiple killing events (Fig. 6E ) and killed faster (Fig. 6F) 
Discussion
Rituximab and trastuzumab are naturally fucosylated antibodies that are key therapeutics in the treatment of various cancers (1, 2, 3, 4) . Their mechanism of action is thought to include ADCC. In preclinical studies, lower antitumor activity with these antibodies was observed in FcγR chain-deficient mice or when wild-type mice were treated with a mutated therapeutic antibody that prevented interaction with the Fc receptor (7) . In clinical studies, a better response rate with rituximab or trastuzumab was observed in patients with the high affinity allele of FcγRIIIa (8, 9) , further supporting the conclusion that ADCC is a significant component of the therapeutic mechanism of action. However, the apparent added benefit afforded by the high affinity allele is not evident in all indications or circumstances since patients with the high and low affinity FcγRIIIa alleles responded equally well to rituximab or trastuzumab for their respective indications in other studies (10) . Although mechanisms to account for these apparent discrepancies are unknown, evidence that ADCC is an important mechanism of action was sufficiently strong that efforts to modify antibodies to increase binding to FcγRIIIa to augment ADCC have been pursued (14, 15, 16) .
Because ADCC is mediated by antibody binding to FcγRIIIa (8, 9) expressed on NK cells (10) , studies were focused on modifying the Fc portion of the antibody to increase ADCC. It was found that removal of the alpha-1, 6 fucose moiety on the N-glycan at Asn-297 of the heavy chain resulted in enhanced interaction between antibody and FcγRIIIa (8, 9, 15, 17) . More importantly, binding enhancement from the removal of fucose directly led to more efficient ADCC (15, 17) and better efficacy in preclinical models (17, 35) . Consistent with those data, our studies also show removal of fucose is sufficient to drive increased NK-cell signaling and activation. One of the biologics borne out of these efforts is obinutuzumab, an anti-CD20 afucosylated antibody that exhibited increased ADCC in preclinical studies and is currently approved for CD20 + hematologic cancers (14) . Obinutuzumab showed increased efficacy in patients, as measured by better overall response rate and higher reported complete remission, with no increase in adverse side effects compared to its fucosylated counterpart rituximab (18) .
Thus, removal of fucose on therapeutic antibodies is a promising technology to improve mobilization of the innate immune system by enhancing NK cell-mediated ADCC (36).
However, cellular mechanisms that account for the enhanced ADCC observed with afucosylated antibodies have not been defined. A better understanding of these cellular mechanisms may help design approaches to make afucosylated antibodies even more effective, or keep them maximally effective, especially in light of new focuses on combination therapies (37) . With development of inhibitors against components of the MAPK, PI3K, and other pathways that cancer cells utilize for growth and survival, these compounds may inadvertently antagonize signaling in immune cells to inhibit therapeutic antibody-mediated ADCC. It is also known that certain chemotherapeutic agents, such as paclitaxel and docetaxel, negatively affect NK-cell cytotoxicity (38) . Therefore, our findings highlight the idea that developing a biologic that potentiates signaling molecules and pathways required for ADCC is extremely important.
Our current studies center on the molecular and cellular processes as well as the cytotoxic properties responsible for the improvement in afucosylated antibody-mediated ADCC. In this series of experiments, we observe an increase in phosphorylation of Lck, CD3ζ, and Zap70 in enhanced in the presence of afucosylated antibodies (41) . Although it is beyond the scope of this study to address the changes in the molecular and cellular processes afforded by afucosylated antibodies in macrophages, our current experiments could lend insight into future studies designed to explore them since macrophages share similar signaling pathways (42) Results from our studies are also consistent with those of previous studies regarding the quantitative gain afforded by using afucosylated antibodies over fucosylated ones. In a study of 4 different NK-cell donors, we determined that, on average, approximately 8.5 times as much fucosylated trastuzumab is required to elicit the same phospho-tyrosine protein signature as afucosylated trastuzumab. This observation is consistent with previous studies demonstrating a 2-11 fold-change in the EC 50 between afucosylated and fucosylated trastuzumab in ADCC assays (17) .
Together, results from these studies serve to advance the understanding of the molecular and cellular mechanisms dictating NK-dependent cytotoxic characteristics by which afucosylated antibodies potentiate ADCC to increase efficacy. They may also guide strategies for combination therapies in oncology indications; the greatest patient benefits may be achieved by 
avoiding combination therapies that compromise NK cell-dependent cytotoxicity, or by including therapies in which NK cell-dependent cytotoxicity either is not compromised or is actually enhanced. on May 15, 2 cancerimmunolres.aacrjournals.org Downloaded from
